Colorcon opens new formulation services facility in Bogota, Colombia
This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more projects.
Colorcon has announced the opening of a new Technical Service, Laboratory and Conference Facility in Bogotá, Colombia, to support market growth and customers across the Andean countries, Central America and the Caribbean. The new facility is strategically located close to transportation hubs to service the pharmaceutical industry across this region.
This specially designed facility has internationally recognized certification for the containment and safe handling of Level II and Level IV APIs, and will provide customer’s faster turnaround on technical services and increased capacity to handle more projects. Carlos LaCruz, Regional Sales Manager explains the importance of this facility to the region “The laboratory is fully equipped to handle Level II and Level IV APIs, for research scale solid dose development. This capability is of particular importance for our customers who require this type of equipment and containment capabilities. We can provide specialized support to accelerate development and commercialization of robust, high quality pharmaceutical drug formulations”.
Plinio Sandoval, Regional Technical Manager stated: “To shorten customer’s formulation development time, Colorcon has invested in new‐instrumented equipment, including high shear granulation, an instrumented press machine, advanced film coating equipment and USP dissolution apparatus. Access to this advanced technology and analytical tools enables more robust formulation development, provides release profiles and ultimately better prediction for scale‐up to manufacturing.”
The Technical Center provides the capacity to increase the educational programs offered, with additional Colorcon Coating and Formulation Schools included to the 2016 schedule; plus a new Formulation School for Matrices addressing the markets’ continuing interest for modified release products.
Perry Cozzone, President — Americas added: “This investment demonstrates Colorcon’s continued commitment to reducing our customer’s time to market and making a positive contribution to their manufacturing quality and production efficiency. It reinforces our dedication to providing best‐in‐class products and services through a network of laboratories positioned close to our customers. The combination of our high quality products and this unprecedented service model is the value of Colorcon.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance